Last reviewed · How we verify
Tociliziumab group
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.
At a glance
| Generic name | Tociliziumab group |
|---|---|
| Sponsor | Biogipuzkoa Health Research Institute |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the interleukin-6 receptor, preventing the activation of the receptor and subsequent signaling pathways that lead to inflammation. This results in a reduction in the production of pro-inflammatory cytokines and a decrease in the severity of inflammatory responses.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic juvenile idiopathic arthritis
Common side effects
- Increased risk of infections
- Neutropenia
- Thrombocytopenia
- Hypersensitivity reactions
- Liver enzyme elevations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |